ANDA 70751, held by Abraxis Pharmaceuticals. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 70751 (Nalbuphine, Nalbuphine Hydrochloride), held by Abraxis Pharmaceuticals, was first approved by FDA on Jul 2, 1986, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 1986 | Original application | Approved | None posted |
| Nalbuphine10MG/ML (10MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Discontinued |
| Nalbuphine Hydrochloride100MG/10ML (10MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Discontinued |
| Feb 20, 1991 | Supplement 10Labeling | Approved | None posted |
| Jan 9, 1990 | Supplement 9Labeling | Approved | None posted |
| Oct 12, 1989 | Supplement 8Labeling | Approved | None posted |
| Jul 2, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters